马上注册，阅读更多内容，享用更多功能！
您需要 登录 才可以下载或查看，没有账号？立即注册 
×
First-line Amivantamab-chemotherapy vs Chemotherapy in NSCLC with EGFR Exon 20 Insertions: Overall Survival from PAPILLON
C. Kim1, K-J. Tang2, B.C. Cho3, L. Paz-Ares4, S. Cheng5, M. Nishio6, M. Thiagarajan7, J.W. Goldman8, J-Y. Hung9, J. Mourão Dias10, S. Popat11, J.K. Sabari12, N. Girard13, A.S. Mansfield14, K. Park15, R.E. Sanborn16, J. Schuchard17, N. Buyukkaramikli18, N. Perualila18, A. Bhattacharya19, P. Barala20, M. Gamil20, S. Gandhy20, J. Man21, S. Shah20, C. Zhou22
PAPILLON：Amivantamab联合化疗治疗EGFR EX20INS晚期非小细胞肺癌 - 非小细胞肺癌
|
